ORCHARD PARK, N.Y., June 9 /PRNewswire-FirstCall/ -- MINRAD International, Inc. (Amex: BUF) today announced it has received approval from the U.S. Food and Drug Administration Center for Veterinary Medicine to market Petrem(TM) (Sevoflurane) inhalation anesthetic. This week they have initiated their US product launch to the veterinary market.
About the Company
MINRAD International, Inc. is an interventional pain management company with real-time image guidance and anesthesia and analgesia product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. Additional information can be found at the company's website, http://www.minrad.com.
The information contained in this news release, other than historical
information, consists of forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These statements may
involve risks and uncertainties that could cause actual results to differ
materially from those described in such statements. Factors that may cause
actual results to differ materially from those expressed or implied by its
forward-looking statements include, but are not limited to, Minrad
International's limited operating history and business development
associated with being a growth stage company; its dependence on key
personnel; its need to attract and retain technical and managerial
personnel; its ability to execute its business strategy; the intense
competition it faces; its ability to protect its intellectual property and
proprietary technologies; its exposure to product liability claims
resulting from the use of its products; general economic and capital market
conditions; financial conditions of its customers and their perception of
its financial condition relative to that of its competitors; as well as
those risks described under the heading "Risk Factors" of Minrad
International's Form 10-KSB-A, filed with the Securities and Exchange
Commission on April 21, 2008.. Although Minrad International, Inc. believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove to
have been correct.
Charles R. Trego, Jr.
Executive Vice President and CFO
|SOURCE MINRAD International, Inc.|
Copyright©2008 PR Newswire.
All rights reserved